Efficacy of intravenous gamma globulin in autoimmune-mediated pediatric blood dyscrasias.
Sixteen pediatric patients diagnosed with a variety of autoimmune-mediated hematocytopenias were treated with one to 50 courses of intravenous gamma globulin (IVIG), pH 4.25, over the course of one to 30 months. Thirteen patients had immune thrombocytopenic purpura (ITP), two had autoimmune neutropenia, and one had autoimmune hemolytic anemia. In one patient, chronic ITP was associated with systemic lupus erythematosis, and in a second patient, acute ITP was the presenting manifestation of infection with human immunodeficiency virus. Initial therapy consisted of 400 mg/kg/dose daily for five days for the first seven patients treated, and 1,000 mg/kg/dose daily for two days for the remaining nine patients. In 15 of 16 patients, there was a response to IVIG therapy. In nine of 16 patients, maintenance IVIG therapy for two to more than 30 months was required. Minimal toxicity was experienced in four of 210 separate infusions. Data are presented to support the use of IVIG in the management of childhood autoimmune disorders.
D000293:Adolescent; D000328:Adult; D000380:Agranulocytosis / Q000628:therapy*; D000744:Anemia, Hemolytic, Autoimmune / Q000628:therapy*; D001327:Autoimmune Diseases / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D009503:Neutropenia / Q000628:therapy*; D011696:Purpura, Thrombocytopenic / Q000628:therapy*
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous